![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RABEP1 |
Gene summary for RABEP1 |
![]() |
Gene information | Species | Human | Gene symbol | RABEP1 | Gene ID | 9135 |
Gene name | rabaptin, RAB GTPase binding effector protein 1 | |
Gene Alias | RAB5EP | |
Cytomap | 17p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q15276 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9135 | RABEP1 | GSM4909297 | Human | Breast | IDC | 1.93e-02 | -1.79e-02 | 0.1517 |
9135 | RABEP1 | GSM4909298 | Human | Breast | IDC | 1.85e-04 | 2.55e-01 | 0.1551 |
9135 | RABEP1 | GSM4909301 | Human | Breast | IDC | 3.09e-13 | 5.10e-01 | 0.1577 |
9135 | RABEP1 | GSM4909305 | Human | Breast | IDC | 3.66e-03 | 2.95e-01 | 0.0436 |
9135 | RABEP1 | GSM4909306 | Human | Breast | IDC | 3.64e-02 | 2.43e-01 | 0.1564 |
9135 | RABEP1 | GSM4909307 | Human | Breast | IDC | 4.46e-05 | 3.44e-01 | 0.1569 |
9135 | RABEP1 | GSM4909308 | Human | Breast | IDC | 1.01e-18 | 5.02e-01 | 0.158 |
9135 | RABEP1 | GSM4909311 | Human | Breast | IDC | 2.49e-07 | -1.33e-01 | 0.1534 |
9135 | RABEP1 | GSM4909319 | Human | Breast | IDC | 7.52e-14 | -1.07e-01 | 0.1563 |
9135 | RABEP1 | M1 | Human | Breast | IDC | 1.56e-09 | 4.82e-01 | 0.1577 |
9135 | RABEP1 | M5 | Human | Breast | IDC | 1.99e-03 | 5.86e-01 | 0.1598 |
9135 | RABEP1 | P1 | Human | Breast | IDC | 1.77e-06 | 2.56e-01 | 0.1527 |
9135 | RABEP1 | DCIS2 | Human | Breast | DCIS | 3.07e-28 | 2.74e-02 | 0.0085 |
9135 | RABEP1 | LZE4T | Human | Esophagus | ESCC | 1.63e-15 | 3.65e-01 | 0.0811 |
9135 | RABEP1 | LZE7T | Human | Esophagus | ESCC | 4.17e-05 | 1.92e-01 | 0.0667 |
9135 | RABEP1 | LZE24T | Human | Esophagus | ESCC | 1.58e-14 | 4.48e-01 | 0.0596 |
9135 | RABEP1 | LZE21T | Human | Esophagus | ESCC | 3.34e-02 | 2.52e-01 | 0.0655 |
9135 | RABEP1 | P1T-E | Human | Esophagus | ESCC | 1.45e-06 | 2.90e-01 | 0.0875 |
9135 | RABEP1 | P2T-E | Human | Esophagus | ESCC | 2.42e-20 | 4.46e-01 | 0.1177 |
9135 | RABEP1 | P4T-E | Human | Esophagus | ESCC | 1.63e-38 | 8.11e-01 | 0.1323 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
GO:000689215 | Esophagus | ESCC | post-Golgi vesicle-mediated transport | 82/8552 | 104/18723 | 4.00e-12 | 1.55e-10 | 82 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:000689315 | Esophagus | ESCC | Golgi to plasma membrane transport | 48/8552 | 60/18723 | 5.11e-08 | 9.16e-07 | 48 |
GO:00610254 | Esophagus | ESCC | membrane fusion | 98/8552 | 163/18723 | 1.39e-04 | 9.41e-04 | 98 |
GO:00481936 | Liver | NAFLD | Golgi vesicle transport | 66/1882 | 296/18723 | 3.66e-10 | 9.30e-08 | 66 |
GO:00068925 | Liver | NAFLD | post-Golgi vesicle-mediated transport | 31/1882 | 104/18723 | 1.70e-08 | 2.03e-06 | 31 |
GO:00068934 | Liver | NAFLD | Golgi to plasma membrane transport | 19/1882 | 60/18723 | 3.60e-06 | 1.42e-04 | 19 |
GO:00988765 | Liver | NAFLD | vesicle-mediated transport to the plasma membrane | 30/1882 | 136/18723 | 2.76e-05 | 7.39e-04 | 30 |
GO:19907786 | Liver | NAFLD | protein localization to cell periphery | 56/1882 | 333/18723 | 8.29e-05 | 1.69e-03 | 56 |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
GO:000689221 | Liver | HCC | post-Golgi vesicle-mediated transport | 77/7958 | 104/18723 | 6.14e-11 | 2.24e-09 | 77 |
GO:009887621 | Liver | HCC | vesicle-mediated transport to the plasma membrane | 92/7958 | 136/18723 | 2.57e-09 | 7.07e-08 | 92 |
GO:000689321 | Liver | HCC | Golgi to plasma membrane transport | 44/7958 | 60/18723 | 1.24e-06 | 1.81e-05 | 44 |
GO:0061025 | Liver | HCC | membrane fusion | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:00068929 | Oral cavity | OSCC | post-Golgi vesicle-mediated transport | 71/7305 | 104/18723 | 1.37e-09 | 3.33e-08 | 71 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa0414442 | Oral cavity | EOLP | Endocytosis | 71/1218 | 251/8465 | 5.28e-09 | 8.97e-08 | 5.29e-08 | 71 |
hsa0414452 | Oral cavity | EOLP | Endocytosis | 71/1218 | 251/8465 | 5.28e-09 | 8.97e-08 | 5.29e-08 | 71 |
hsa0414461 | Oral cavity | NEOLP | Endocytosis | 62/1112 | 251/8465 | 3.56e-07 | 4.92e-06 | 3.09e-06 | 62 |
hsa0414471 | Oral cavity | NEOLP | Endocytosis | 62/1112 | 251/8465 | 3.56e-07 | 4.92e-06 | 3.09e-06 | 62 |
hsa0414425 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
hsa04144111 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
hsa0414426 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
hsa0414435 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RABEP1 | insertion | Frame_Shift_Ins | novel | c.1879_1880insTAACTCTTCCATCTTCT | p.Gln627LeufsTer11 | p.Q627Lfs*11 | Q15276 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD | ||
RABEP1 | insertion | Frame_Shift_Ins | novel | c.2586_2587insGCAAGAACAAT | p.Ter863AlafsTer12 | p.*863Afs*12 | Q15276 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD | ||
RABEP1 | SNV | Missense_Mutation | c.1567N>T | p.His523Tyr | p.H523Y | Q15276 | protein_coding | deleterious(0.02) | benign(0.06) | TCGA-EJ-A65F-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | PD | |
RABEP1 | SNV | Missense_Mutation | novel | c.530N>G | p.Ala177Gly | p.A177G | Q15276 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
RABEP1 | SNV | Missense_Mutation | novel | c.1439C>T | p.Thr480Ile | p.T480I | Q15276 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-3M-AB46-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | fluorouracil | CR |
RABEP1 | SNV | Missense_Mutation | c.2011N>A | p.Pro671Thr | p.P671T | Q15276 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RABEP1 | SNV | Missense_Mutation | c.841C>A | p.Gln281Lys | p.Q281K | Q15276 | protein_coding | tolerated(0.08) | probably_damaging(0.952) | TCGA-FP-7829-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
RABEP1 | deletion | Frame_Shift_Del | novel | c.2265delA | p.Gly756AspfsTer7 | p.G756Dfs*7 | Q15276 | protein_coding | TCGA-HU-A4GT-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | copolang | SD | ||
RABEP1 | insertion | Frame_Shift_Ins | novel | c.460_461insAAAAAATAACC | p.Ile154LysfsTer5 | p.I154Kfs*5 | Q15276 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
RABEP1 | insertion | Nonsense_Mutation | novel | c.1954_1955insCAAACTAAAGGAG | p.Leu652ProfsTer3 | p.L652Pfs*3 | Q15276 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | lithium | LITHIUM | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | amisulpride | AMISULPRIDE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | valproic acid | 28694205 | ||
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | risperidone | RISPERIDONE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | olanzapine | OLANZAPINE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | mirtazapine | MIRTAZAPINE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | clozapine | CLOZAPINE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | aripiprazole | ARIPIPRAZOLE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | quetiapine | QUETIAPINE | 28694205 | |
9135 | RABEP1 | CLINICALLY ACTIONABLE, GROWTH FACTOR | paliperidone | PALIPERIDONE | 28694205 |
Page: 1 |